z-logo
Premium
Altered circulating endothelial progenitor cells in patients with keloid
Author(s) -
Zhang G.Y.,
Wu L.C.,
Liao T.,
Chen G.,
Chen Y.H.,
Meng X.C.,
Wang A.Y.,
Chen S.Y.,
Lin K.,
Lin D.M.,
Gao W.Y.,
Li Q.F.
Publication year - 2016
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12695
Subject(s) - keloid , medicine , progenitor cell , cd34 , vascular endothelial growth factor , flow cytometry , cancer research , vegf receptors , immunology , pathology , stem cell , biology , microbiology and biotechnology
Summary Evidence has suggested that vascular endothelial growth factor ( VEGF ), a crucial growth factor in regulating endothelial progenitor cells ( EPC s), plays a central role in keloid formation. However, the levels of circulating EPC s in patients with keloid have not yet been explored. The aim of this study was to determine the number of circulating EPC s in patients with keloid. Circulating EPC s (defined as CD 45− CD 34+ CD 133+ VEGFR 2+cells) and VEGF levels from 39 patients with keloid and 22 healthy controls ( HC s) were assessed by flow cytometry and ELISA , respectively. EPC s were detectable in the peripheral blood of patients with keloid. The number of circulating EPC s and the levels of plasma VEGF were significantly higher in patients with keloid than in HC s. However, no correlation was found between the number of circulating EPC s and the serum VEGF levels. This study provides the first evidence that EPC s are increased in the peripheral blood of patients with keloid. Understanding the roles of EPC s in keloid fromation may lead to the development of novel therapeutic strategies for keloid.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here